These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1433200)

  • 21. A new series of photoactivatable and iodinatable linear vasopressin antagonists.
    Carnazzi E; Aumelas A; Barberis C; Guillon G; Seyer R
    J Med Chem; 1994 Jun; 37(12):1841-9. PubMed ID: 8021923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel approach to the design of synthetic radioiodinated linear V1A receptor antagonists of vasopressin.
    Manning M; Bankowski K; Barberis C; Jard S; Elands J; Chan WY
    Int J Pept Protein Res; 1992; 40(3-4):261-7. PubMed ID: 1478783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel strategies for the design of receptor-selective vasopressin analogues: Aib-substitution and retro-inverso transformation.
    Howl J; Prochazka Z; Wheatley M; Slaninová J
    Br J Pharmacol; 1999 Oct; 128(3):647-52. PubMed ID: 10516644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent V2 vasopressin antagonists with structural changes at their C-terminals.
    Sawyer WH; Bankowski K; Misicka A; Nawrocka E; Kruszynski M; Stoev S; Klis WA; Przybylski JP; Manning M
    Peptides; 1988; 9(1):157-63. PubMed ID: 3362743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probing the V1a vasopressin receptor binding site with pyroglutamate-substituted linear antagonists.
    Howl J; Yarwood NJ; Stock D; Wheatley M
    Neuropeptides; 1996 Feb; 30(1):73-9. PubMed ID: 8868303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
    Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
    J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced selectivity of oxytocin antagonists containing sarcosine in position 7.
    Pavo I; Slaninova J; Klein U; Fahrenholz F
    J Med Chem; 1994 Jan; 37(2):255-9. PubMed ID: 7507528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surprising pharmacological activity of analogues designed by substitution of position 3 in arginine vasopressin (AVP) and 8-D-arginine vasopressin with L-2-napthylalanine.
    Lammek B; Konieczna E; Trzeciak HI; Kozłowski A; Szymkowiak J; Stojko R; Kupryszewski G
    J Pharm Pharmacol; 1996 Mar; 48(3):316-9. PubMed ID: 8737061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological activities of some new arginine vasopressin analogues containing unusual amino acids.
    Varga C; Somlai C; Baláspiri L; László FA
    Acta Physiol Hung; 1993; 81(2):183-92. PubMed ID: 8197874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor.
    Thibonnier M; Auzan C; Madhun Z; Wilkins P; Berti-Mattera L; Clauser E
    J Biol Chem; 1994 Feb; 269(5):3304-10. PubMed ID: 8106369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
    J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2-O-alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: highly specific and potent antidiuretic agonists.
    Lammek B; Bankowski K; Misicka A; Manning M; Seto J; Sawyer WH
    J Med Chem; 1989 Jan; 32(1):244-7. PubMed ID: 2909737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proconvulsive effect of vasopressin; mediation by a putative V2 receptor subtype in the central nervous system.
    Croiset G; De Wied D
    Brain Res; 1997 Jun; 759(1):18-23. PubMed ID: 9219858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
    Guillon G; Pena A; Murat B; Derick S; Trueba M; Ventura MA; Szeto HH; Wo N; Stoev S; Cheng LL; Manning M
    J Pept Sci; 2006 Mar; 12(3):190-8. PubMed ID: 16130178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological characterization of V1a vasopressin receptors in the rat cortical collecting duct.
    Ammar A; Roseau S; Butlen D
    Am J Physiol; 1992 Apr; 262(4 Pt 2):F546-53. PubMed ID: 1533099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays.
    Chan WY; Wo NC; Stoev ST; Cheng LL; Manning M
    Exp Physiol; 2000 Mar; 85 Spec No():7S-18S. PubMed ID: 10795902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highly potent 1-aminocyclohexane-1-carboxylic acid substituted V2 agonists of arginine vasopressin.
    Kowalczyk W; Prahl A; Derdowska I; Dawidowska O; Slaninová J; Lammek B
    J Med Chem; 2004 Nov; 47(24):6020-4. PubMed ID: 15537356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vasopressin-induced sensitization: involvement of neurohypophyseal peptide receptors.
    Poulin P; Szot P; Dorsa DM; Pittman QJ
    Eur J Pharmacol; 1995 Dec; 294(1):29-39. PubMed ID: 8788413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the disulfide bridge and the C-terminal tripeptide in the antidiuretic action of vasopressin in man and the rat.
    Cort JH; Schück O; Stríbrná J; Skopková J; Jost K; Mulder JL
    Kidney Int; 1975 Nov; 8(5):292-302. PubMed ID: 1195561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of AVP and oxytocin on insulin release: involvement of V1b receptors.
    Lee B; Yang C; Chen TH; al-Azawi N; Hsu WH
    Am J Physiol; 1995 Dec; 269(6 Pt 1):E1095-100. PubMed ID: 8572202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.